Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Eblasakimab - CSL

Next Previous
X
Search
Drug Profile

Eblasakimab - CSL

Alternative Names: ASLAN 004; CSL 334; IL-13R - Merck; IL-13Rα1 project; MK 6105

Latest Information Update: 24 Jul 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck & Co; Zenyth Therapeutics
  • Developer ASLAN Pharmaceuticals; CSL
  • Class Anti-inflammatories; Antiasthmatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 13 inhibitors; Interleukin 4 inhibitors; Interleukin-13 receptor alpha1 subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Asthma; Atopic dermatitis
  • Discontinued Chronic obstructive pulmonary disease

Most Recent Events

  • 24 Jul 2024 Phase-II clinical trials in Asthma (Parenteral) (CSL pipeline, July 2024)
  • 24 Jul 2024 Phase-II clinical trials in Atopic dermatitis (Parenteral) (CSL pipeline, July 2024)
  • 17 Jul 2024 Discontinued - Phase-II for Atopic dermatitis (Treatment-experienced) in Canada, USA (SC)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top